Vedeck\u00fd z\u00e1ujem o Pinealon vzr\u00e1stol v\u010faka jeho potenci\u00e1lnym neuroprotekt\u00edvnym vlastnostiam v experiment\u00e1lnych modeloch Alzheimerovej choroby. Hoci doteraz neboli uskuto\u010dnen\u00e9 rozsiahle klinick\u00e9 sk\u00fa\u0161ania na \u013eu\u010foch, ktor\u00e9 by hodnotili Pinealon ako lie\u010dbu Alzheimerovej choroby, nieko\u013eko predklinick\u00fdch \u0161t\u00fadi\u00ed analyzovalo jeho vplyv na pre\u017eitie neur\u00f3nov, integritu synapsi\u00ed a procesy spojen\u00e9 s neurodegener\u00e1ciou (1,2).<\/p>\n
Jednu z najv\u00fdznamnej\u0161\u00edch \u0161t\u00fadi\u00ed vykonali Kraskovskaya a spolupracovn\u00edci s vyu\u017eit\u00edm in vitro modelu amyloidom indukovanej synaptotoxicity, ktor\u00fd odzrkad\u013euje niektor\u00e9 aspekty po\u0161kodenia neur\u00f3nov pozorovan\u00e9 pri Alzheimerovej chorobe (1). V \u0161t\u00fadii boli prim\u00e1rne neur\u00f3ny hipokampu my\u0161\u00ed vystaven\u00e9 amyloidovej toxicite, ktor\u00e1 zvy\u010dajne vedie k zn\u00ed\u017eeniu po\u010dtu zrel\u00fdch dendritick\u00fdch v\u00fdbe\u017ekov podie\u013eaj\u00facich sa na neur\u00f3novej komunik\u00e1cii. Lie\u010dba peptidom EDR (Pinealon) v koncentr\u00e1cii 200 ng\/ml zv\u00fd\u0161ila po\u010det hubovit\u00fdch dendritick\u00fdch v\u00fdbe\u017ekov o 71% a obnovila ich po\u010det na norm\u00e1lne hodnoty (1).<\/p>\n
H\u00fasenicovit\u00e9 dendritick\u00e9 t\u0155ne s\u00fa vysoko stabiln\u00e9 synaptick\u00e9 \u0161trukt\u00fary, ktor\u00e9 zohr\u00e1vaj\u00fa k\u013e\u00fa\u010dov\u00fa \u00falohu pri u\u010den\u00ed, formovan\u00ed pam\u00e4te a dlhodobom uchov\u00e1van\u00ed inform\u00e1ci\u00ed. Strata t\u00fdchto \u0161trukt\u00far je \u010dasto spojen\u00e1 so zhor\u0161en\u00edm kognit\u00edvnych funkci\u00ed a neurodegenerat\u00edvnymi ochoreniami. Schopnos\u0165 Pinealonu obnovi\u0165 hustotu dendritick\u00fdch t\u0155\u0148ov nazna\u010duje, \u017ee m\u00f4\u017ee pom\u00e1ha\u0165 pri zachovan\u00ed neuron\u00e1lnych spojen\u00ed a podporova\u0165 neuroplasticitu v podmienkach neurodegenerat\u00edvneho stresu (1).<\/p>\n
Dodatkov\u00e9 d\u00f4kazy poskytli Khavinson a jeho spolupracovn\u00edci, ktor\u00ed sk\u00famali kr\u00e1tke bioregula\u010dn\u00e9 peptidy na my\u0161om modeli Alzheimerovej choroby (2). V\u00fdsledky uk\u00e1zali neuroprotekt\u00edvne \u00fa\u010dinky spojen\u00e9 so zv\u00fd\u0161enou odolnos\u0165ou neur\u00f3nov a ochranou pred neurodegenerat\u00edvnymi zmenami s\u00favisiacimi s vekom. Pinealon bol klasifikovan\u00fd do skupiny epigenetick\u00fdch peptidov schopn\u00fdch regulova\u0165 bunkov\u00fa aktivitu a podporova\u0165 pre\u017eitie neur\u00f3nov v experiment\u00e1lnych podmienkach (2).<\/p>\n
Za pozorovan\u00e9 \u00fa\u010dinky m\u00f4\u017ee zodpoveda\u0165 nieko\u013eko biologick\u00fdch mechanizmov. Laborat\u00f3rne \u0161t\u00fadie nazna\u010duj\u00fa, \u017ee Pinealon m\u00f4\u017ee zni\u017eova\u0165 oxida\u010dn\u00fd stres, obmedzova\u0165 po\u0161kodenie buniek, ovplyv\u0148ova\u0165 g\u00e9nov\u00fa expresiu a podporova\u0165 vitalitu neur\u00f3nov (2 \u2013 4). Tieto \u00fa\u010dinky m\u00f4\u017eu spolo\u010dne pom\u00e1ha\u0165 pri zachovan\u00ed synaptick\u00fdch \u0161trukt\u00far a obmedzova\u0165 niektor\u00e9 stresov\u00e9 faktory spojen\u00e9 s neurodegener\u00e1ciou.<\/p>\n
Aj ke\u010f s\u00fa tieto v\u00fdsledky s\u013eubn\u00e9, s\u00fa\u010dasn\u00e9 d\u00f4kazy poch\u00e1dzaj\u00fa hlavne z bunkov\u00fdch a zvierac\u00edch \u0161t\u00fadi\u00ed. Zatia\u013e neboli publikovan\u00e9 rozsiahle klinick\u00e9 \u0161t\u00fadie hodnotn\u00e9 liek Pinealon pri Alzheimerovej chorobe. Preto by sa Pinealon mal v s\u00fa\u010dasnosti pova\u017eova\u0165 za experiment\u00e1lny neuroprotekt\u00edvny peptid, ktor\u00fd si vy\u017eaduje \u010fal\u0161\u00ed v\u00fdskum, a nie za zaveden\u00fa lie\u010dbu Alzheimerovej choroby.<\/p>\n
V ruskej literat\u00fare o bioregula\u010dn\u00fdch peptidoch sa Pinealon \u010dasto klasifikuje ako geroprotekt\u00edvum. Tento term\u00edn ozna\u010duje l\u00e1tky, ktor\u00e9 m\u00f4\u017eu podporova\u0165 zdrav\u00e9 starnutie, zachovanie fyziologick\u00fdch funkci\u00ed a potenci\u00e1lne spoma\u013eova\u0165 niektor\u00e9 aspekty biologick\u00e9ho starnutia. V\u00fdznamn\u00e1 \u010das\u0165 t\u00fdchto v\u00fdskumov poch\u00e1dza z pr\u00e1c Vladimira Khavinsona a jeho spolupracovn\u00edkov, ktor\u00ed analyzovali kr\u00e1tke regula\u010dn\u00e9 peptidy z h\u013eadiska ich potenci\u00e1lnej \u00falohy pri dlhovekosti a udr\u017eiavan\u00ed zdravia v star\u0161om veku (5).<\/p>\n
Jedn\u00fdm z najv\u00fdznamnej\u0161\u00edch v\u00fdskumov t\u00fdkaj\u00facich sa Pinealonu a zdrav\u00e9ho starnutia bol v\u00fdskum Meshchaninova a spolupracovn\u00edkov na osob\u00e1ch vo veku 41 a\u017e 83 rokov s chronickou polymorbiditou a remisn\u00fdm organick\u00fdm syndr\u00f3mom mozgu (5). V\u00fdskumn\u00edci hodnotili vplyv Pinealonu a in\u00e9ho peptidov\u00e9ho bioregulatora, Vesugenu, na biomarkery spojen\u00e9 s biologick\u00fdm vekom a funk\u010dn\u00fdm stavom organizmu.<\/p>\n
Vedci zaznamenali, \u017ee Pinealon vyvolal v\u00fdznamn\u00e9 anabolick\u00e9 \u00fa\u010dinky a zlep\u0161il funk\u010dn\u00fa aktivitu centr\u00e1lneho nervov\u00e9ho syst\u00e9mu a in\u00fdch d\u00f4le\u017eit\u00fdch org\u00e1nov (5). Tieto zmeny boli spojen\u00e9 so spomalen\u00fdm tempom biologick\u00e9ho starnutia hodnoten\u00fdm na z\u00e1klade analyzovan\u00fdch biomarkerov. Autori uviedli, \u017ee Pinealon vykazuje geroprotekt\u00edvne aj neuroprotekt\u00edvne vlastnosti, ktor\u00e9 m\u00f4\u017eu podporova\u0165 zdrav\u00e9 starnutie u os\u00f4b so sympt\u00f3mami funk\u010dn\u00fdch por\u00fach s\u00favisiacich s vekom.<\/p>\n
\u0160t\u00fadia tie\u017e nazna\u010dovala, \u017ee Pinealon by mohol ovplyv\u0148ova\u0165 metabolick\u00e9 a bunkov\u00e9 dr\u00e1hy zapojen\u00e9 do procesu starnutia. Napriek tomu, \u017ee sa po\u010das lie\u010dby zlep\u0161ilo nieko\u013eko biomarkerov starnutia, peptid neovplyvnil kondenz\u00e1ciu chromat\u00ednu, \u010do nazna\u010dovalo absenciu detekovate\u013en\u00fdch nepriazniv\u00fdch \u00fa\u010dinkov na stabilitu genetick\u00e9ho materi\u00e1lu v experiment\u00e1lnych podmienkach (5). V\u00fdskumn\u00edci to pova\u017eovali za v\u00fdznamn\u00fd bezpe\u010dnostn\u00fd ukazovate\u013e a odporu\u010dili \u010fal\u0161ie \u0161t\u00fadie.<\/p>\n
Nieko\u013eko laborat\u00f3rnych \u0161t\u00fadi\u00ed poskytuje potenci\u00e1lne mechanistick\u00e9 vysvetlenia t\u00fdchto pozorovan\u00ed. Bolo preuk\u00e1zan\u00e9, \u017ee Pinealon zni\u017euje oxida\u010dn\u00fd stres, podporuje pre\u017eitie neur\u00f3nov, reguluje dr\u00e1hy s\u00favisiace so seroton\u00ednom a ovplyv\u0148uje expresiu g\u00e9nov prostredn\u00edctvom epigenetick\u00fdch mechanizmov (2\u20134,6). Ke\u010f\u017ee oxida\u010dn\u00fd stres a naru\u0161en\u00e1 bunkov\u00e1 regul\u00e1cia s\u00fa pova\u017eovan\u00e9 za prispievate\u013eov k biologick\u00e9mu starnutiu, tieto \u00fa\u010dinky m\u00f4\u017eu \u010diasto\u010dne vysvetli\u0165 pozorovan\u00e9 geroprotekt\u00edvne vlastnosti Pinealonu.<\/p>\n
Napriek s\u013eubn\u00fdm v\u00fdsledkom v\u00fdskum Pinealonu a procesov starnutia zost\u00e1va v porovnan\u00ed s podrobnej\u0161ie presk\u00faman\u00fdmi intervenciami s\u00favisiacimi s dlhovekos\u0165ou relat\u00edvne obmedzen\u00fd. Na ur\u010denie, \u010di zlep\u0161enie biomarkerov biologick\u00e9ho veku vedie k v\u00fdznamn\u00fdm dlhodob\u00fdm zdravotn\u00fdm pr\u00ednosom, s\u00fa potrebn\u00e9 \u010fal\u0161ie klinick\u00e9 \u0161t\u00fadie. Napriek tomu dostupn\u00e9 \u00fadaje radia Pinealon medzi lep\u0161ie presk\u00faman\u00e9 bioregula\u010dn\u00e9 peptidy v oblasti zdrav\u00e9ho starnutia a neurogerontol\u00f3gie.<\/p>\n
Sen je jednou z naj\u010dastej\u0161ie diskutovan\u00fdch t\u00e9m medzi \u013eu\u010fmi, ktor\u00ed sa zauj\u00edmaj\u00fa o Pinealon. Z\u00e1ujem o tak\u00e9to fr\u00e1zy ako \u201ePinealon a sp\u00e1nok\u201d, \u201ePinealon na sp\u00e1nok\u201d, \u201ePinealon peptide sleep\u201d, \u201ePinealon REM sleep\u201d a \u201ePinealon circadian rhythm\u201d sa v posledn\u00fdch rokoch v\u00fdrazne zv\u00fd\u0161il. Pri hodnoten\u00ed t\u00fdchto tvrden\u00ed je v\u0161ak d\u00f4le\u017eit\u00e9 rozli\u0161ova\u0165 medzi vedeck\u00fdmi d\u00f4kazmi a anekdotick\u00fdmi pozorovaniami.<\/p>\n
V s\u00fa\u010dasnosti \u017eiadna kontrolovan\u00e1 klinick\u00e1 \u0161t\u00fadia nepreuk\u00e1zala, \u017ee by Pinealon zlep\u0161il kvalitu sp\u00e1nku, zv\u00fd\u0161il podiel REM f\u00e1zy, reguloval cirkadi\u00e1nny rytmus alebo lie\u010dil poruchy sp\u00e1nku. Existuj\u00faca vedeck\u00e1 literat\u00fara sa zameriava predov\u0161etk\u00fdm na neuroprotekciu, regul\u00e1ciu oxida\u010dn\u00e9ho stresu, kognit\u00edvne funkcie, expresiu seroton\u00ednu a zdrav\u00e9 starnutie, nie v\u0161ak na v\u00fdsledky s\u00favisiace so sp\u00e1nkom (2-6).<\/p>\n
Jedn\u00fdm z mo\u017en\u00fdch vysvetlen\u00ed z\u00e1ujmu o Pinealon a sp\u00e1nok s\u00fa \u0161t\u00fadie nazna\u010duj\u00face, \u017ee tento peptid stimuluje expresiu g\u00e9nu, ktor\u00fd k\u00f3duje tryptof\u00e1n hydroxyl\u00e1zu \u2013 enz\u00fdm obmedzuj\u00faci r\u00fdchlos\u0165 synt\u00e9zy s\u00e9roton\u00ednu (6). S\u00e9roton\u00edn je prekurzorom melaton\u00ednu a hr\u00e1 z\u00e1sadn\u00fa \u00falohu pri regul\u00e1cii cyklu sp\u00e1nku a bdenia, n\u00e1lady a neurologick\u00fdch funkci\u00ed. V\u00fdskumn\u00edci nazna\u010duj\u00fa, \u017ee schopnos\u0165 Pinealonu ovplyv\u0148ova\u0165 dr\u00e1hy s\u00favisiace so s\u00e9roton\u00ednom m\u00f4\u017ee prispieva\u0165 k jeho neuroprotekt\u00edvnym a geroprotekt\u00edvnym \u00fa\u010dinkom (6).<\/p>\n
Ke\u010f\u017ee s\u00e9roton\u00edn \u00fazko s\u00favis\u00ed s regul\u00e1ciou sp\u00e1nku, niektor\u00ed v\u00fdskumn\u00edci vyslovili hypot\u00e9zu, \u017ee Pinealon m\u00f4\u017ee nepriamo ovplyv\u0148ova\u0165 procesy s\u00favisiace so sp\u00e1nkom. V s\u00fa\u010dasnosti v\u0161ak ch\u00fdbaj\u00fa priame klinick\u00e9 d\u00f4kazy podporuj\u00face zlep\u0161enie kvality sp\u00e1nku, d\u013a\u017eky sp\u00e1nku, REM f\u00e1zy alebo regul\u00e1cie cirkadi\u00e1nneho rytmu.<\/p>\n
Spr\u00e1vy z internetov\u00fdch komun\u00edt a online diskusie poskytuj\u00fa dodato\u010dn\u00e9 inform\u00e1cie vysvet\u013euj\u00face z\u00e1ujem o Pinealon v tejto oblasti. V anekdotick\u00fdch opisoch niektor\u00ed jedinci hl\u00e1sia subjekt\u00edvne zlep\u0161enie kvality sp\u00e1nku, lep\u0161ie zapam\u00e4tanie snov, intenz\u00edvnej\u0161ie sn\u00edvanie a v\u00e4\u010d\u0161\u00ed pocit odd\u00fdchnutia po prebuden\u00ed. In\u00ed uv\u00e1dzaj\u00fa, \u017ee si pred span\u00edm aplikuj\u00fa Pinealon do nosa, preto\u017ee poci\u0165uj\u00fa benefity spojen\u00e9 so sp\u00e1nkom a snami.<\/p>\n
Je potrebn\u00e9 zd\u00f4razni\u0165, \u017ee tieto pozorovania s\u00fa anekdotick\u00e9 a neboli potvrden\u00e9 v kontrolovan\u00fdch klinick\u00fdch \u0161t\u00fadi\u00e1ch. Na pou\u017e\u00edvate\u013esk\u00e9 sk\u00fasenosti m\u00f4\u017ee ma\u0165 vplyv mnoho faktorov, vr\u00e1tane o\u010dak\u00e1van\u00ed, pou\u017eit\u00fdch d\u00e1vkovac\u00edch protokolov, individu\u00e1lnej neuroch\u00e9mie, s\u00fa\u010dasne u\u017e\u00edvan\u00fdch doplnkov a placebo efektu.<\/p>\n
Vzh\u013eadom na obmedzen\u00fd po\u010det klinick\u00fdch \u00fadajov nie je v s\u00fa\u010dasnosti mo\u017en\u00e9 formulova\u0165 odpor\u00fa\u010dania zalo\u017een\u00e9 na d\u00f4kazoch t\u00fdkaj\u00face sa optim\u00e1lneho \u010dasu pod\u00e1vania Pinealonu na ovplyvnenie sp\u00e1nku. Bud\u00face v\u00fdskumy kvality sp\u00e1nku, REM f\u00e1zy, cirkadi\u00e1nnej biol\u00f3gie a regul\u00e1cie neurotransmiterov m\u00f4\u017eu pom\u00f4c\u0165 objasni\u0165, \u010di Pinealon m\u00e1 v\u00fdznamn\u00fd vplyv na parametre s\u00favisiace so sp\u00e1nkom.<\/p>\n
V\u0161eobecne vedeck\u00e9 d\u00f4kazy v s\u00fa\u010dasnosti potvrdzuj\u00fa \u00falohu pinealonu v neur\u00f3novej regul\u00e1cii a dr\u00e1hach s\u00favisiacich so seroton\u00ednom, zatia\u013e \u010do tvrdenia o priazniv\u00fdch \u00fa\u010dinkoch na sp\u00e1nok zost\u00e1vaj\u00fa predbe\u017en\u00e9 a zakladaj\u00fa sa prim\u00e1rne na anekdotick\u00fdch pozorovaniach, nie na overen\u00fdch klinick\u00fdch d\u00f4kazoch.<\/p>\n
Obsah je ur\u010den\u00fd v\u00fdlu\u010dne na vzdel\u00e1vacie a informa\u010dn\u00e9 \u00fa\u010dely a nemal by by\u0165 interpretovan\u00fd ako lek\u00e1rska rada, diagn\u00f3za, lie\u010dba ani odborn\u00e9 odpor\u00fa\u010danie. Pr\u00edpravok Pinealon nebol schv\u00e1len\u00fd Americk\u00fdm \u00faradom pre potraviny a lie\u010div\u00e1 (FDA), Eur\u00f3pskou liekovou agent\u00farou (EMA) ani v\u00e4\u010d\u0161inou in\u00fdch regula\u010dn\u00fdch org\u00e1nov na lie\u010dbu Alzheimerovej choroby, por\u00fach sp\u00e1nku, chor\u00f4b s\u00favisiacich so starnut\u00edm alebo ak\u00fdchko\u013evek in\u00fdch lek\u00e1rskych indik\u00e1ci\u00ed. V\u00e4\u010d\u0161ina dostupn\u00fdch \u00fadajov poch\u00e1dza z predklinick\u00fdch \u0161t\u00fadi\u00ed, \u0161t\u00fadi\u00ed na zvierat\u00e1ch a obmedzen\u00e9ho po\u010dtu \u0161t\u00fadi\u00ed na \u013eu\u010foch. Na lep\u0161ie ur\u010denie \u00fa\u010dinnosti, bezpe\u010dnosti a dlhodob\u00e9ho \u00fa\u010dinku pr\u00edpravku Pinealon v r\u00f4znych popul\u00e1ci\u00e1ch s\u00fa potrebn\u00e9 \u010fal\u0161ie, dobre navrhnut\u00e9 klinick\u00e9 \u0161t\u00fadie.<\/p>\n
(1)<\/strong> Kraskovskaya, N. A., Kukanova, E. O., Lin\u2019kova, N. S., Popugaeva, E. A., & Khavinson, V. K. (2017). Tripeptidy obnovuj\u00fa po\u010det neuron\u00e1lnych t\u0155\u0148ov in vitro v podmienkach modelov\u00e9ho Alzheimerovej choroby.<\/em>. Bulletin experiment\u00e1lnej biol\u00f3gie a medic\u00edny, 163<\/em>(4), 547\u2013550. https:\/\/doi.org\/10.1007\/s10517-017-3847-2<\/a><\/span> (2)<\/strong> Khavinson, V., Ilina, A., Kraskovskaya, N., Linkova, N., Kolchina, N., Mironova, E., Erofeev, A., & Petukhov, M. (2021). Neuroprotekt\u00edvne \u00fa\u010dinky tripeptidov \u2013 epigenetick\u00fdch regul\u00e1torov na my\u0161om modeli Alzheimerovej choroby<\/em>. Farmaceutik\u00e1, 14<\/em>(6), 515. https:\/\/doi.org\/10.3390\/ph14060515<\/a><\/span> (3)<\/strong> Khavinson, V., Ribakova, Y., Trofimova, S. a kol. (2011). Pinealon zvy\u0161uje \u017eivotaschopnos\u0165 buniek potla\u010den\u00edm hladiny vo\u013en\u00fdch radik\u00e1lov a aktiv\u00e1ciou proliferat\u00edvnych procesov<\/em>. V\u00fdskum omladzovania, 14<\/em>(5), 517\u2013523. https:\/\/doi.org\/10.1089\/rej.2011.1172<\/a><\/span> (4)<\/strong> Fedoreyeva, L. I., Kireev, I. I., Khavinson, V. K., & Vanyushin, B. F. (2011). Penetr\u00e1cia kr\u00e1tkych fluorescen\u010dne zna\u010den\u00fdch peptidov do jadra v bunk\u00e1ch HeLa a in vitro \u0161pecifick\u00e1 interakcia peptidov s deoxyribooligonucleotidmi a DNA<\/em>. Bioch\u00e9mia (Moskva), 76<\/em>(11), 1210\u20131219. https:\/\/doi.org\/10.1134\/S0006297911110022<\/a><\/span> (5)<\/strong> Meshchaninov, V. N., Tkachenko, E. L., Zharkov, S. V., Gavrilov, I. V., & Katyreva, Y. E. (2015). Vplyv syntetick\u00fdch peptidov na starnutie pacientov s chronickou polymorbiditou a syndr\u00f3mom organick\u00e9ho po\u0161kodenia centr\u00e1lnej nervovej s\u00fastavy v remisii<\/em>. Pokroky v gerontol\u00f3gii, 28<\/em>(1), 62\u201367.<\/span> (6)<\/strong> Khavinson, V. K., Lin\u2019kova, N. S., Tarnovskaya, S. I., Umnov, R. S., Elashkina, E. V., & Durnova, A. O. (2014). Kr\u00e1tke peptidy stimuluj\u00fa expresiu s\u00e9roton\u00ednu v bunk\u00e1ch mozgovej k\u00f4ry<\/em>. Bulletin experiment\u00e1lnej biol\u00f3gie a medic\u00edny, 157<\/em>(1), 77\u201380. https:\/\/doi.org\/10.1007\/s10517-014-2496-y<\/a><\/span> V\u00fdskum Pinealonu a Alzheimerovej choroby Vedeck\u00fd z\u00e1ujem o Pinealon vzr\u00e1stol kv\u00f4li jeho potenci\u00e1lnym neuroprotekt\u00edvnym vlastnostiam v experiment\u00e1lnych modeloch Alzheimerovej choroby. Hoci sa doteraz neuskuto\u010dnili...<\/p>","protected":false},"author":7908,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[253],"tags":[],"class_list":["post-51175","post","type-post","status-publish","format-standard","hentry","category-kategoria-pinealon","beh-no-thumb"],"_links":{"self":[{"href":"https:\/\/bioevidencehub.com\/sk\/wp-json\/wp\/v2\/posts\/51175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bioevidencehub.com\/sk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bioevidencehub.com\/sk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bioevidencehub.com\/sk\/wp-json\/wp\/v2\/users\/7908"}],"replies":[{"embeddable":true,"href":"https:\/\/bioevidencehub.com\/sk\/wp-json\/wp\/v2\/comments?post=51175"}],"version-history":[{"count":0,"href":"https:\/\/bioevidencehub.com\/sk\/wp-json\/wp\/v2\/posts\/51175\/revisions"}],"wp:attachment":[{"href":"https:\/\/bioevidencehub.com\/sk\/wp-json\/wp\/v2\/media?parent=51175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bioevidencehub.com\/sk\/wp-json\/wp\/v2\/categories?post=51175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bioevidencehub.com\/sk\/wp-json\/wp\/v2\/tags?post=51175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
PubMed: https:\/\/pubmed.ncbi.nlm.nih.gov\/28853087\/<\/a><\/span><\/p>\n
Odkaz na \u010dasopis: https:\/\/www.mdpi.com\/1424-8247\/14\/6\/515<\/a><\/span><\/p>\n
Odkaz na \u010dasopis: https:\/\/journals.sagepub.com\/doi\/abs\/10.1089\/rej.2011.1172<\/a><\/span><\/p>\n
Odkaz na \u010dasopis: https:\/\/link.springer.com\/article\/10.1134\/S0006297911110022<\/a><\/span><\/p>\n
PubMed: https:\/\/pubmed.ncbi.nlm.nih.gov\/26390612\/<\/a><\/span><\/p>\n
PubMed: https:\/\/pubmed.ncbi.nlm.nih.gov\/24909721\/<\/a><\/span><\/p>","protected":false},"excerpt":{"rendered":"